Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| WD 40 COWDFC · Entity 4262 | Director | February 05, 2026 | February 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
WD 40 CO
Report date February 05, 2026 · Filed February 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,898 |
Reported balance
After 2026-02-05 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-02-05 · Purchase · Acquired 424 · Balance 6,898 F1: Represents: (i) 1,275 shares acquired via stock purchases by Reporting Owner, and (ii) 5,623 vested RSUs treated as common stock equivalents. Following termination of Reporting Person's service as a director, vested RSUs will be settled with Issuer's common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents: (i) 1,275 shares acquired via stock purchases by Reporting Owner, and (ii) 5,623 vested RSUs treated as common stock equivalents. Following termination of Reporting Person's service as a director, vested RSUs will be settled with Issuer's common stock.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
RESMED INC
Report date June 30, 2023 · Filed June 30, 2023
Section 16 reporting ended · disclosed 2023-06-30. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| ResMed Common StockSEC Table I · non-derivative | Direct | 89,729 |
Reported balance
Holding disclosure · report date 2023-06-30 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 89,729 |
SEQUENOM INC
Report date September 07, 2016 · Filed September 07, 2016
Section 16 reporting ended · disclosed 2016-09-07. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2016-09-07 transaction · row 1
1 source rowRow 1 · 2016-09-07 · Other · Disposed 112,969 · Balance 0 F1: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated July 26, 2016, among the Issuer, Laboratory Corporation of America Holdings, a Delaware corporation ("Parent"), and Savoy Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser") in exchange for a cash consideration of $2.40 per share, without interest, subject to any required withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger"). |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.11 · Expires 2026-06-14 | Direct | 0 |
Reported balance
After 2016-09-07 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2016-09-07 · Disposition to issuer · Disposed 20,000 · Balance 0 F2: This option was cancelled in the Merger in exchange for a cash payment equal to $2.40 per share (without interest) minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated July 26, 2016, among the Issuer, Laboratory Corporation of America Holdings, a Delaware corporation ("Parent"), and Savoy Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser") in exchange for a cash consideration of $2.40 per share, without interest, subject to any required withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger").
F2: This option was cancelled in the Merger in exchange for a cash payment equal to $2.40 per share (without interest) minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 03, 2021 Filed Jun 7, 2021 17:10 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 1,487 | $207.00 | $307,809.00 |
DisclosureSEC source: 0001127602-21-019336 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,387 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · balance_after: Includes 66.72 shares of ResMed stock purchased on April 30, 2021, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| May 03, 2021 Filed May 4, 2021 20:23 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 1,487 | $190.50 | $283,273.50 |
DisclosureSEC source: 0001127602-21-015196 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,807 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| April 05, 2021 Filed Apr 6, 2021 15:12 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 1,487 | $196.15 | $291,675.05 |
DisclosureSEC source: 0001127602-21-013306 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,294 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| March 03, 2021 Filed Mar 4, 2021 19:09 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 1,487 | $191.80 | $285,206.60 |
DisclosureSEC source: 0001127602-21-009363 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,781 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 18:11 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 1,487 | $204.42 | $303,972.54 |
DisclosureSEC source: 0001127602-21-004154 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,268 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| January 18, 2021 Filed Jan 20, 2021 00:59 UTC | RESMED INC RMD · Entity 2692 | GrantResMed Common Stock | 1,548 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-002066 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,755 F1 · shares: Represents performance-based restricted stock units granted on November 21, 2019. The shares were earned on January 18, 2021, when the compensation committee certified that the performance metrics were met for this portion of the grant. The earned units remain subject to time-vesting requirements, and are scheduled to vest on the three-year anniversary of the grant, assuming continued service through the vesting date. Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 21:50 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 1,487 | $213.24 | $317,087.88 |
DisclosureSEC source: 0001127602-21-000635 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,207 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| December 08, 2020 Filed Dec 11, 2020 00:51 UTC | WD 40 CO WDFC · Entity 4262 | GrantCommon Stock | 475 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-20-020919 · doc1.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,779 F1 · shares: Restricted Stock Units (Common Stock equivalents) were granted pursuant to the WD-40 Company 2016 Stock Incentive Plan for non-elective and elective portions of annual director compensation in accordance with the Issuer's Directors' Compensation Policy and Election Plan. The Restricted Stock Units will be settled solely with Issuer Common Stock upon termination of the reporting person's service as a director. F1 · price: Restricted Stock Units (Common Stock equivalents) were granted pursuant to the WD-40 Company 2016 Stock Incentive Plan for non-elective and elective portions of annual director compensation in accordance with the Issuer's Directors' Compensation Policy and Election Plan. The Restricted Stock Units will be settled solely with Issuer Common Stock upon termination of the reporting person's service as a director. F2 · balance_after: Total represents 2,779 Restricted Stock Units (Common Stock equivalents). Read SEC document |
| December 03, 2020 Filed Dec 7, 2020 17:41 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 1,487 | $208.36 | $309,831.32 |
DisclosureSEC source: 0001127602-20-030668 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,694 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| November 23, 2020 Filed Nov 24, 2020 18:31 UTC | RESMED INC RMD · Entity 2692 | GiftResMed Common Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-029909 · form4.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,181 F1 · kind: Gift of shares to The San Diego Foundation, a 501(c)(3) nonprofit organization. Mr. Pendarvis has no beneficial interest, control or dispositive power over the gifted shares. Read SEC document |
| November 20, 2020 Filed Nov 24, 2020 18:31 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 1,176 | $0.00 Strike: $84.98 | $0.00 |
DisclosureSEC source: 0001127602-20-029909 · form4.xml · derivative · entry 3 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,519 Underlying: ResMed Common Stock · 1,176 shares Expires 2024-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| November 20, 2020 Filed Nov 24, 2020 18:31 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 1,176 | $84.98 | $99,936.48 |
DisclosureSEC source: 0001127602-20-029909 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,181 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 19, 2020 Filed Nov 21, 2020 01:19 UTC | RESMED INC RMD · Entity 2692 | GrantResMed Common Stock Options · Derivative | 7,702 | $0.00 Strike: $211.76 | $0.00 |
DisclosureSEC source: 0001127602-20-029776 · form4.xml · derivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,702 Underlying: ResMed Common Stock · 7,702 shares Expires 2027-11-19 F1 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 annually each November 11, 2021, 2022 and 2023. Read SEC document |
| November 19, 2020 Filed Dec 1, 2020 21:24 UTC Amendment | RESMED INC RMD · Entity 2692 | GrantResMed Common Stock Options · Derivative | 7,849 | $0.00 Strike: $211.76 | $0.00 |
DisclosureSEC source: 0001127602-20-030207 · form4a.xml · derivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,849 Underlying: ResMed Common Stock · 7,849 shares Expires 2027-11-19 F1 · shares: Corrects original reported option grant for updated Black-Scholes valuation. F1 · derivative.underlying_shares: Corrects original reported option grant for updated Black-Scholes valuation. Read SEC document |
| November 17, 2020 Filed Nov 19, 2020 20:47 UTC | RESMED INC RMD · Entity 2692 | Tax withholdingResMed Common Stock | 12,445 | $214.74 | $2,672,439.30 |
DisclosureSEC source: 0001127602-20-029557 · form4.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,005 F2 · kind: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/16/2017. Read SEC document |
| November 17, 2020 Filed Nov 19, 2020 20:47 UTC | RESMED INC RMD · Entity 2692 | GrantResMed Common Stock | 22,310 | $214.74 | $4,790,849.40 |
DisclosureSEC source: 0001127602-20-029557 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,450 F1 · kind: Represents performance-based restricted stock units granted on November 16, 2017. The shares were earned on November 17, 2020, when the compensation committee certified that the performance metrics were met. Read SEC document |
| November 11, 2020 Filed Nov 14, 2020 00:02 UTC | RESMED INC RMD · Entity 2692 | Tax withholdingResMed Common Stock | 490 | $212.11 | $103,933.90 |
DisclosureSEC source: 0001127602-20-029032 · form4.xml · nonDerivative · entry 3 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,140 F4 · kind: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/21/2019. Read SEC document |
| November 11, 2020 Filed Nov 14, 2020 00:02 UTC | RESMED INC RMD · Entity 2692 | Tax withholdingResMed Common Stock | 722 | $212.11 | $153,143.42 |
DisclosureSEC source: 0001127602-20-029032 · form4.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,630 F3 · kind: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/14/2018. Read SEC document |
| November 11, 2020 Filed Nov 14, 2020 00:02 UTC | RESMED INC RMD · Entity 2692 | Tax withholdingResMed Common Stock | 855 | $212.11 | $181,354.05 |
DisclosureSEC source: 0001127602-20-029032 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,352 F1 · kind: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/16/2017. F2 · balance_after: Includes 78.84 shares of ResMed stock purchased on October 31, 2020, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| November 03, 2020 Filed Nov 5, 2020 19:01 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 5,918 | $0.00 Strike: $57.76 | $0.00 |
DisclosureSEC source: 0001127602-20-028220 · form4.xml · derivative · entry 3 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: ResMed Common Stock · 5,918 shares Expires 2023-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| November 03, 2020 Filed Nov 5, 2020 19:01 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 5,918 | $201.14 | $1,190,363.68 |
DisclosureSEC source: 0001127602-20-028220 · form4.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,128 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $197.28 to 203.32. The price reported above reflects the weighted average sale price. Read SEC document |
| November 03, 2020 Filed Nov 5, 2020 19:01 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 5,918 | $57.76 | $341,823.68 |
DisclosureSEC source: 0001127602-20-028220 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,046 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| October 05, 2020 Filed Oct 6, 2020 22:08 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 5,919 | $0.00 Strike: $57.76 | $0.00 |
DisclosureSEC source: 0001127602-20-026627 · form4.xml · derivative · entry 3 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,918 Underlying: ResMed Common Stock · 5,919 shares Expires 2023-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| October 05, 2020 Filed Oct 6, 2020 22:08 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 5,919 | $170.07 | $1,006,620.65 |
DisclosureSEC source: 0001127602-20-026627 · form4.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,128 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $168.72 to 171.06. The price reported above reflects the weighted average sale price. Read SEC document |
| October 05, 2020 Filed Oct 6, 2020 22:08 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 5,919 | $57.76 | $341,881.44 |
DisclosureSEC source: 0001127602-20-026627 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,047 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| September 03, 2020 Filed Sep 4, 2020 21:00 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 5,919 | $0.00 Strike: $57.76 | $0.00 |
DisclosureSEC source: 0001127602-20-024769 · form4.xml · derivative · entry 3 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,837 Underlying: ResMed Common Stock · 5,919 shares Expires 2023-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| September 03, 2020 Filed Sep 4, 2020 21:00 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 5,919 | $177.52 | $1,050,714.24 |
DisclosureSEC source: 0001127602-20-024769 · form4.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,128 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $175.44 to 181.64. The price reported above reflects the weighted average sale price. Read SEC document |
| September 03, 2020 Filed Sep 4, 2020 21:00 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 5,919 | $57.76 | $341,881.44 |
DisclosureSEC source: 0001127602-20-024769 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,047 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| August 13, 2020 Filed Aug 17, 2020 15:35 UTC | RESMED INC RMD · Entity 2692 | GrantResMed Common Stock | 2,966 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-023639 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,128 F1 · kind: Represents performance-based restricted stock units granted on November 21, 2019. The shares were earned on August 13, 2020, when the compensation committee certified that the performance metrics were met. Stock units vest 1/3 each year on the anniversary of the grant. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 00:01 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 5,919 | $0.00 Strike: $57.76 | $0.00 |
DisclosureSEC source: 0001127602-20-022759 · form4.xml · derivative · entry 3 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,756 Underlying: ResMed Common Stock · 5,919 shares Expires 2023-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F4 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 00:01 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 5,919 | $201.99 | $1,195,593.02 |
DisclosureSEC source: 0001127602-20-022759 · form4.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,162 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $200.61 to $202.98. The price reported above reflects the weighted average sale price. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 00:01 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 5,919 | $57.76 | $341,881.44 |
DisclosureSEC source: 0001127602-20-022759 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,081 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · balance_after: Balance adjusted by duplicate reporting of 780 performance units earned on June 4, 2020 originally reported as banked shares on April 19, 2018. Read SEC document |
| July 06, 2020 Filed Jul 7, 2020 19:14 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 5,919 | $0.00 Strike: $57.76 | $0.00 |
DisclosureSEC source: 0001127602-20-021267 · form4.xml · derivative · entry 3 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,675 Underlying: ResMed Common Stock · 5,919 shares Expires 2023-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| July 06, 2020 Filed Jul 7, 2020 19:14 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 5,919 | $194.64 | $1,152,090.14 |
DisclosureSEC source: 0001127602-20-021267 · form4.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,942 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $192.70 to 197.30. The price reported above reflects the weighted average sale price. Read SEC document |
| July 06, 2020 Filed Jul 7, 2020 19:14 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 5,919 | $57.76 | $341,881.44 |
DisclosureSEC source: 0001127602-20-021267 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,861 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| June 04, 2020 Filed Jun 8, 2020 20:39 UTC | RESMED INC RMD · Entity 2692 | Tax withholdingResMed Common Stock | 3,483 | $160.82 | $560,136.06 |
DisclosureSEC source: 0001127602-20-019135 · form4.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,942 F2 · kind: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 6/1/2017. Read SEC document |
| June 04, 2020 Filed Jun 8, 2020 20:39 UTC | RESMED INC RMD · Entity 2692 | GrantResMed Common Stock | 7,022 | $160.82 | $1,129,278.04 |
DisclosureSEC source: 0001127602-20-019135 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,425 F1 · kind: Represents performance-based restricted stock units granted on June 1, 2017. The shares were earned on June 4, 2020, when the compensation committee certified that the performance metrics were met. Read SEC document |
| June 03, 2020 Filed Jun 5, 2020 16:32 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 5,919 | $0.00 Strike: $57.76 | $0.00 |
DisclosureSEC source: 0001127602-20-018985 · form4.xml · derivative · entry 3 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,594 Underlying: ResMed Common Stock · 5,919 shares Expires 2023-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| June 03, 2020 Filed Jun 5, 2020 16:32 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 5,919 | $160.61 | $950,660.06 |
DisclosureSEC source: 0001127602-20-018985 · form4.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,403 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $159.05 to 162.18. The price reported above reflects the weighted average sale price. Read SEC document |
| June 03, 2020 Filed Jun 5, 2020 16:32 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 5,919 | $57.76 | $341,881.44 |
DisclosureSEC source: 0001127602-20-018985 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,322 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 01:37 UTC | RESMED INC RMD · Entity 2692 | Tax withholdingResMed Common Stock | 239 | $161.12 | $38,507.68 |
DisclosureSEC source: 0001127602-20-018554 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,403 F1 · kind: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 6/1/2017. Read SEC document |
| May 04, 2020 Filed May 6, 2020 20:31 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 4,737 | $0.00 Strike: $58.24 | $0.00 |
DisclosureSEC source: 0001127602-20-015628 · form4.xml · derivative · entry 3 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: ResMed Common Stock · 4,737 shares Expires 2022-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F4 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| May 04, 2020 Filed May 6, 2020 20:31 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 4,737 | $155.06 | $734,515.43 |
DisclosureSEC source: 0001127602-20-015628 · form4.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,642 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $153.33 to 158.02. The price reported above reflects the weighted average sale price. F3 · balance_after: Includes 78.522 shares of ResMed stock purchased on April 30, 2020, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| May 04, 2020 Filed May 6, 2020 20:31 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 4,737 | $58.24 | $275,882.88 |
DisclosureSEC source: 0001127602-20-015628 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,379 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| April 03, 2020 Filed Apr 7, 2020 00:38 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 4,739 | $0.00 Strike: $58.24 | $0.00 |
DisclosureSEC source: 0001127602-20-013346 · form4.xml · derivative · entry 3 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,737 Underlying: ResMed Common Stock · 4,739 shares Expires 2022-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| April 03, 2020 Filed Apr 7, 2020 00:38 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 4,739 | $152.63 | $723,302.67 |
DisclosureSEC source: 0001127602-20-013346 · form4.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,564 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $148.99 to 154.59. The price reported above reflects the weighted average sale price. Read SEC document |
| April 03, 2020 Filed Apr 7, 2020 00:38 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 4,739 | $58.24 | $275,999.36 |
DisclosureSEC source: 0001127602-20-013346 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,303 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| March 03, 2020 Filed Mar 5, 2020 19:33 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 4,739 | $0.00 Strike: $58.24 | $0.00 |
DisclosureSEC source: 0001127602-20-009574 · form4.xml · derivative · entry 3 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,476 Underlying: ResMed Common Stock · 4,739 shares Expires 2022-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| March 03, 2020 Filed Mar 5, 2020 19:33 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 4,739 | $166.65 | $789,757.19 |
DisclosureSEC source: 0001127602-20-009574 · form4.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,564 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $163.15 to 171.16. The price reported above reflects the weighted average sale price. Read SEC document |
| March 03, 2020 Filed Mar 5, 2020 19:33 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 4,739 | $58.24 | $275,999.36 |
DisclosureSEC source: 0001127602-20-009574 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,303 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.